Abstract
Microvascular abnormalities, both in function and structure, lead to impaired tissue perfusion that may affect multiple tissues and organs and seem to be involved in target-organ damage and complications observed in obesity and insulin resistance. In general, vascular remodeling of small arteries associated to cardiometabolic diseases seems to be hypertrophic and it is associated to increased extracellular matrix deposition, although specific vascular beds might show different structural patterns. The mechanisms by which obesity, insulin resistance and/or hyperinsulimemia determine vascular disease are not clear yet but might include hemodynamic factors such as hypertension, activation of the sympathetic nervous and the renin-angiotensin-aldosterone systems, metabolic factors such as insulin and advanced glycation end products and other factors such as adipokines, inflammation or oxidative stress. Exercise and weight loss as well as blockade of the renin-angiotensin system seem to be efficient actions to correct vascular alterations in patients. This review aims to examine the existing literature on structural alterations in small vessels associated to insulin resistance and obesity. A description about the underlying mechanisms possibly responsible of the vascular alterations is also provided. Moreover, effects of pharmacological and non pharmacological strategies that could modify these vascular alterations are summarized.
Keywords: Obesity, insulin resistance, remodeling, small arteries, stiffness.
Current Vascular Pharmacology
Title:Small Artery Remodeling in Obesity and Insulin Resistance
Volume: 12 Issue: 3
Author(s): Ana M. Briones, Rosa Aras-Lopez, Maria J. Alonso and Mercedes Salaices
Affiliation:
Keywords: Obesity, insulin resistance, remodeling, small arteries, stiffness.
Abstract: Microvascular abnormalities, both in function and structure, lead to impaired tissue perfusion that may affect multiple tissues and organs and seem to be involved in target-organ damage and complications observed in obesity and insulin resistance. In general, vascular remodeling of small arteries associated to cardiometabolic diseases seems to be hypertrophic and it is associated to increased extracellular matrix deposition, although specific vascular beds might show different structural patterns. The mechanisms by which obesity, insulin resistance and/or hyperinsulimemia determine vascular disease are not clear yet but might include hemodynamic factors such as hypertension, activation of the sympathetic nervous and the renin-angiotensin-aldosterone systems, metabolic factors such as insulin and advanced glycation end products and other factors such as adipokines, inflammation or oxidative stress. Exercise and weight loss as well as blockade of the renin-angiotensin system seem to be efficient actions to correct vascular alterations in patients. This review aims to examine the existing literature on structural alterations in small vessels associated to insulin resistance and obesity. A description about the underlying mechanisms possibly responsible of the vascular alterations is also provided. Moreover, effects of pharmacological and non pharmacological strategies that could modify these vascular alterations are summarized.
Export Options
About this article
Cite this article as:
Briones M. Ana, Aras-Lopez Rosa, Alonso J. Maria and Salaices Mercedes, Small Artery Remodeling in Obesity and Insulin Resistance, Current Vascular Pharmacology 2014; 12 (3) . https://dx.doi.org/10.2174/1570161112666140423221319
DOI https://dx.doi.org/10.2174/1570161112666140423221319 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Formulation and Ex Vivo Evaluation of Buccal Tablets of Isradipine in a β- Cyclodextrin Complex to Improve the Photostability
Current Drug Therapy Effect of Administration of Nandrolone Decanoate upon Aldosterone Concentration and Serum Na+/K+ Levels in Albino Mice
Cardiovascular & Hematological Agents in Medicinal Chemistry The Activated Endocannabinoid System in Atherosclerosis: Driving Force or Protective Mechanism?
Current Drug Targets Pharmacotherpy and Alzheimer’s Disease: The M-Drugs (Melatonin, Minocycline, Modafinil, and Memantine) Approach
Current Pharmaceutical Design The Renin-Angiotensin System and Advanced Glycation End-Products in Diabetic Retinopathy: Impacts and Synergies.
Current Clinical Pharmacology Fetal Undernutrition and the Programming of Blood Pressure
Current Nutrition & Food Science Brain Angiotensin II Involvement in Chronic Mental Disorders
Protein & Peptide Letters The Role of PPARs in Pathological Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design RAAS Inhibition and Renal Protection
Current Pharmaceutical Design The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research Poor Response to Antiplatelet Drugs. An Important Issue in Drug-Eluting Stents.
Current Clinical Pharmacology Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Monoaminergic Neurotransmission: The History of the Discovery of Antidepressants from 1950s Until Today
Current Pharmaceutical Design Blockade of the Renin-Angiotensin-Aldosterone System: Effects on Hypertensive Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry Stenting Renal Artery Stenosis: What is the Fuss All About?
Reviews on Recent Clinical Trials Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies
Current Medicinal Chemistry Update on the Role of Neutrophils in Atherosclerotic Plaque Vulnerability
Current Drug Targets NAD(P)H Oxidase Activation: A Potential Target Mechanism for Diabetic Vascular Complications, Progressive β-Cell Dysfunction and Metabolic Syndrome
Current Drug Targets Carbon Monoxide, A Two-Face for the Protection of the Liver
Current Pharmaceutical Biotechnology Synthesis of 3,4–Dihydropyrimidin–2-ones (DHPMs) Using Highly Efficient Recyclable Silica Supported Rhodium Chloride as Heterogeneous Catalyst and their Anti-Neuroinflammatory Activity
Letters in Drug Design & Discovery